About 20 former Pfizer Inc. employees and contractors in Groton have been certified as eligible for federal benefits because their jobs were sent overseas, the state Department of Labor said today.
June 12, 2013
Pfizer Inc. announced today that it will receive about $1.38 billion in a settlement with Teva Pharmaceuticals Industries Ltd. and Sun Pharmaceutical Industries Ltd. over a nearly decade-old patent case.
June 8, 2013
Pfizer Inc. is partnering with a San Francisco firm to discover next-generation cancer treatments.
The drug-industry blog FiercePharma reported this week that Pfizer has agreed to pay CytomX Therapeutics $25 million up front and as much as...
June 5, 2013
Pfizer Inc. has expanded a drug-development partnership with the University of California at San Francisco.
According to UCSF, the expansion of Pfizer's Centers for Therapeutic...
May 24, 2013
A Harvard University genetics expert has been named director of Farmington's Jackson Laboratory for Genomic Medicine.
World-renowned scientist Charles Lee, best known for a genetic discovery involving...
May 23, 2013
Pfizer Inc. announced this week that its Groton laboratories will be supporting 30 organizations in southeastern Connecticut, New Haven and Rhode Island through its competitive grants program.
Organizations can apply online for the...
May 18, 2013
Pfizer Inc. has announced the closure of an Irish production plant that will lead to 136 job cuts.
The New York-based drug giant said the closure of its Little Island manufacturing plant in Cork was the result of "changing global demand"...
May 17, 2013
Nearly 400 former workers at Pfizer Inc., including some who were working at the Groton laboratories as contractors for ExecuPharm Inc., have been told they qualify for federal benefits after their jobs were moved overseas.
May 11, 2013
Dublin-based biotech Amarin Corp. plc's stock took a ride upward Friday, one day after releasing first-quarter financial results that gave an early glimpse of how sales of its newly approved heart medication, Vascepa, are proceeding.
May 10, 2013
As more top-selling drugs went off patent in 2012, Americans for the first time in decades spent less money on medicines than they had the previous year.
The New York-based IMS Institute for Healthcare...
May 10, 2013
Pfizer Inc. is inviting investors and the public to attend a webcast at 11 a.m. today in which Mikael Dolsten, president of its research-and-development division worldwide, speaks during the Morgan Stanley 2013 R&D Seminar called Reigniting...
May 8, 2013
Senior managers of Amarin Corp. plc, a biotech company with research headquarters in Groton, will discuss the company's first-quarter financial results at 4:30 p.m. Thursday during a conference call.
To participate in the call, dial...
May 1, 2013
New drugs spurred along by research at Pfizer Inc. laboratories in Groton couldn't provide enough lift to make up for losses in the company's established portfolio as the firm announced disappointing first-quarter financial results...
April 30, 2013
Drug giant Pfizer Inc. has joined forces with competitor Merck & Co. Inc. to co-develop a new medicine for patients with type 2 diabetes, the companies announced Monday.
Pfizer, which has a research-and-development site in Groton, currently...
April 30, 2013
Pfizer Inc. reported disappointing first-quarter financial results this morning, with dramatically increased profits failing to mask weaknesses in pharmaceutical sales.
April 27, 2013
The board of directors of Pfizer Inc. declared Thursday a 24-cent second-quarter 2013 dividend on the company's common stock, payable June 4 to shareholders of record at the close of business on May 10.
April 27, 2013
Pfizer Inc. said Thursday that the European Union's committee of medical experts has rejected the company's drug Xeljanz for patients with rheumatoid arthritis.
The European Medicines Agency committee...
April 24, 2013
Amarin Corp. plc, the Irish drug company with research headquarters in Groton, announced Tuesday that U.S. regulators have agreed to review its fish-oil medication Vascepa for an expanded group of patients not covered by similar prescription...